ACNEGO ADVANCE CREAM Clinical Monograph & Batch COA
Certified DCGI Formulation Literature (PDF)
ACNEGO ADVANCE CREAM
Hydroquinone 2% w/w + Tretinoin 0.025% w/w + Mometasone Furoate 0.1% w/w
ACNEGO ADVANCE CREAM (Hydroquinone 2% w/w + Tretinoin 0.025% w/w + Mometasone Furoate 0.1% w/w) is manufactured under strict WHO-GMP compliance for maximum bioavailability and therapeutic efficacy.
Clinical Pharmacology & Therapeutic Profile
Comprehensive therapeutic guidelines for medical practitioners and institutional procurement
Therapeutic Indications
Mechanism of Action (MOA)
The active pharmacological principles in ACNEGO ADVANCE CREAM deliver targeted therapeutic action through standardized systemic bioavailability and verified pharmacodynamics.
As directed by the registered medical practitioner. Strictly adhere to full course duration.
Well tolerated under clinical supervision. Contraindicated in patients with hypersensitivity to active ingredients.
Store in a cool place below 25°C. Do not freeze. Replace cap tightly after use.
WHO-GMP Certified Purity
Manufactured in state-of-the-art HVAC controlled cleanrooms with 100% active ingredient bio-potency and analytical batch testing.
Alu-Alu Moisture Barrier
Superior barrier protection against tropical humidity, preventing physical degradation and guaranteeing 24-month stability.
Exclusive District Monopoly
Strict PCD franchise monopoly allocation ensuring zero price competition and complete territory protection for our partners.
Technical Product Specifications
Active Medical Composition
ACNEGO ADVANCE CREAM features Hydroquinone 2% w/w + Tretinoin 0.025% w/w + Mometasone Furoate 0.1% w/w prepared to high pharmaceutical purity standards.
*Disclaimer: Formulations are intended solely for distribution to licensed practitioners, hospitals, and pharmacies. Dosage must adhere to medical advice.
Customer & Clinical Reviews
Real feedback from registered physicians, stockists, PCD franchise partners, and verified buyers.
Based on 1 verified review
Marked reduction in inflammatory acne lesions without peeling
ACNEGO Advance Cream has demonstrated high clinical satisfaction for grade II papulopustular acne vulgaris. The micro-emulsion vehicle penetrates the follicular infundibulum smoothly without causing the intense erythema or xerosis frequently observed with harsh retinoid formulations. Patients appreciate the non-comedogenic matte finish.
Questions Regarding ACNEGO ADVANCE CREAM
What is the therapeutic indication and composition of ACNEGO ADVANCE CREAM?
ACNEGO ADVANCE CREAM contains Hydroquinone 2% w/w + Tretinoin 0.025% w/w + Mometasone Furoate 0.1% w/w indicated for Indicated for therapeutic management within specified clinical indications under qualified physician guidance. as formulated by Sygnus Biotech.
What packaging presentations are available for ACNEGO ADVANCE CREAM?
ACNEGO ADVANCE CREAM is supplied in tamper-evident 15g / 30g Laminated Aluminum Barrier Tube, engineered with barrier foil protection to ensure a 24 to 36 month shelf life.
Is monopoly PCD franchise territory available for ACNEGO ADVANCE CREAM?
Yes, Sygnus Biotech grants exclusive district-wise monopoly marketing rights for ACNEGO ADVANCE CREAM along with promotional visual aids, product cards, and marketing support.
What is the regulatory schedule and minimum order quantity (MOQ)?
ACNEGO ADVANCE CREAM is categorized as Schedule H with an introductory PCD franchise MOQ of 100 units per batch.
Related Formulations in Cream & Ointment
View all Cream & Ointment →
VIVO+ GEL
Diclofenac Sodium 1% w/v + Linseed Oil 3% w/w + Methyl Salicylate 10% w/w +Capsaicin 0.025% w/w Menthol 5% w/w + Benzyl Alcohol 1% w/w
OXIDINE TOOTH PASTE
Pottasium Nitrate + Sodium Monofluorophosphate + Triclosan
VIVO GEL
Diclofenac Sodium 1% w/w + Linseed Oil 3% w/w + Menthol 5% w/w + Methyl Salicylate 10% w/w